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KRASG12D and TP53R167H Cooperate 
to Induce Pancreatic Ductal 
Adenocarcinoma in Sus scrofa Pigs
Daniel R. Principe1, Nana Haahr Overgaard2,3, Alex J. Park  4, Andrew M. Diaz4, 
Carolina Torres4, Ronald McKinney4, Matthew J. Dorman4, Karla Castellanos4, 
Regina Schwind5, David W. Dawson6, Ajay Rana7, Ajay Maker7, Hidayatullah G. Munshi8, 
Lauretta A. Rund  3,9, Paul J. Grippo4 & Lawrence B. Schook3,5
Although survival has improved in recent years, the prognosis of patients with advanced pancreatic 
ductal adenocarcinoma (PDAC) remains poor. Despite substantial differences in anatomy, physiology, 
genetics, and metabolism, the overwhelming majority of preclinical testing relies on transgenic mice. 
Hence, while mice have allowed for tremendous advances in cancer biology, they have been a poor 
predictor of drug performance/toxicity in the clinic. Given the greater similarity of sus scrofa pigs 
to humans, we engineered transgenic sus scrofa expressing a LSL-KRASG12D-TP53R167H cassette. By 
applying Adeno-Cre to pancreatic duct cells in vitro, cells self-immortalized and established tumors in 
immunocompromised mice. When Adeno-Cre was administered to the main pancreatic duct in vivo, pigs 
developed extensive PDAC at the injection site hallmarked by excessive proliferation and desmoplastic 
stroma. This serves as the first large animal model of pancreatic carcinogenesis, and may allow for 
insight into new avenues of translational research not before possible in rodents.
Genetically modified mouse models have revolutionized cancer research, allowing for faithful and reproducible 
histotypes closely representing those observed in human patients. This is particularly true in recent years, largely 
attributed to the availability of mix-and-match systems such as Cre/lox and tTA/TRE1. These respective technol-
ogies continue to provide tissue specific recombination and gene inducibility, while allowing for more clinically 
relevant models of non-syndromic cancers. By employing such model systems, mice have offered invaluable and 
unprecedented insight into the etiology of diseases that generally present in late stages, such as pancreatic ductal 
adenocarcinoma (PDAC)2. However, while mice have inarguably allowed for tremendous advances in cancer, 
they have considerable limitations as a disease model due to vastly different physiology3, and the conceptual leap 
from mouse to human has been a culprit in the failure of many promising preclinical therapies.
The most obvious of these limitations is the mouse anatomy. The average human is roughly 2,500–3,000 times 
the size of an average mouse, severely limiting the use of mice for studies focused on surgical or radiologic inter-
ventions. Importantly, the domestic pig (sus scrofa) is now emerging as a viable model for cancer and many other 
human diseases. While the mouse (Mus musculus) genome is approximately 14% smaller than that of humans 
(2.5 Gb compared to 2.9 Gb)4, the sus scrofa genome is more similar at 2.7 Gb5,6. Furthermore, the linkage con-
servation between humans and pigs is considerably more extensive than that between humans and mice7. As a 
result, pigs are more closely related to humans with respect to anatomy, physiology, and immunology8, and have 
the potential to more accurately represent a variety of human diseases, particularly those affecting the pancreas.
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The porcine pancreas is far more human-like than that of rodents, with comparable anatomical orientation 
and localization9. For instance, pig pancreata generally exhibit three distinct lobes, with the duodenal lobe corre-
sponding to the head of the human pancreas, the connecting lobe being analogous to the uncinate process, and 
the splenic lobe corresponding to the tail/body of the pancreas9. In light of these many similarities, modeling 
pancreatic cancer in pigs would provide the opportunity to conduct surgical and radiologic studies never before 
possible, and may offer additional insight into disease pathogenesis due to the size and composition of the gland.
Currently, the most widely used mouse model of pancreatic cancer consists of concurrent KRASG12D and 
TP53172H mutations targeted to the exocrine pancreas under the Pdx-1 promoter10. This model (KPC) has been 
used extensively and is considered a gold standard within the field. We sought to generate a similar histoype in sus 
scrofa pigs to provide a more physiologically and anatomically relevant model. We first generated pigs harboring 
analogous KRASG12D and TP53R167H mutations, which are observed in approximately 95% and 50% of human 
PDAC patients respectively11,12. After demonstrating the ability of these transgenes to induce adenocarcinomatous 
transformation of pig duct cells ex vivo, we administered an Adenoviral Cre Recombinase (Adeno-Cre) to the pig 
pancreas in vivo. Following refinement of the delivery system, these mutations successfully induced pancreatic 
neoplasms and cancer in the pig, providing the first documented large animal model of pancreatic carcinoma.
Materials and Methods
Transgenesis. LSL-KRASG12D-TP53R167H pigs were generated as previously described13.
Pigs and In Vivo Imaging. All animal procedures were approved by the University of Illinois Institutional 
Animal Care and Use Committee. All pigs used were of the LSL-KRASG12D-TP53R167H transgenic line. 
LSL-KRASG12D-TP53R167H pigs were dosed with 4 × 109 PFU of Ad5CMVCre-eGFP (Adeno-Cre), either directly 
into the body of the pancreas or into the pancreatic duct pushed toward the pancreas. For all cases the pancreas 
was accessed surgically through a ventral midline incision. Anesthesia was induced with TKX (Telazol, Ketamine, 
Xylazine), intubated and maintained in a surgical plane of anesthesia with Isoflurane.
Following recovery, all animals were monitored for general health, weight and periodic blood chemistry eval-
uation. For euthanasia, each animal was sedated and euthanized with sodium pentobarbital overdose (Fatal plus 
10 cc/100 lbs.). All animals underwent gross and histopathologic evaluation. Tissues were then collected and sub-
ject to gross and histopathologic analysis.
For in vivo imaging, animals were sedated as described previously and 120 ml of the contrast agent Iohexal 
(Omnipaque) was delivered intravenously, allowing for visualization of potential pathologies by contrast com-
puted tomography (CT). Scans were limited to the cranial abdomen.
Cell Culture. The pancreas from a two-month old female pig was collected and immediately cut into 1 mm3 
pieces in ice cold DMEM/F12 media with 20% animal serum complex, penicillin (100 units/mL), and strepto-
mycin (100 μg/mL). Tissue was transferred to 50 ml conical tubes and washed with cold media and transferred 
to a sterile hood. Tissues were washed again and incubated with Collagenase Ia (1 mg/ml) and 0.25 mg/ml of 
trypsin inhibitor for five minutes at 37 °C. The Collagenase reaction was quenched with PBS with 20% animal 
serum complex and the cells washed. The reaction was similarly quenched with PBS with 20% animal serum 
complex and the cells washed in fresh culture media with 20% heat-inactivated fetal bovine serum (FBS), pen-
icillin (100 units/mL), and streptomycin (100 μg/mL). The cells were then seeded on six well plates and allowed 
to adhere. Once the cells were seeded, they were infected with Adeno-Cre at a 200 to 500 MOI. The media was 
changed after six hours and cells maintained at 37 °C with 5% CO2.
Mice. 5 × 106 PORC1 cells suspended in100 μl of Matrigel, (BD Biosciences, San Diego, CA, USA) and injected 
subcutaneously into 3 SCID mice (NOD.CB17-Prkdcscid/ JAX, Bar Harbor, ME, USA). Tumor growth data was 
monitored for up to 100 days. SQ tumors were routinely measured and overall health was assessed by weight and 
visual inspection. Mice were sacrificed by cervical dislocation, and tissues collected and subject to histopathology. 
All animal procedures were approved by the University of Illinois Institutional Animal Care and Use Committee.
RT-PCR. RNA was extracted using Trizol (Fischer-Scientific, Waltham, MA). Quantity/quality was 
evaluated by spectrophotometer (Nanogen Inc, San Diego, CA) and integrity confirmed via gel electro-
phoresis. cDNA was then synthesized using the High-Capacity cDNA Reverse Transcription Kit per man-
ufacturer specifications (Fischer-Scientific, Waltham, MA) and rtPCR was conducted with SYBR Green 
and commercially available TP53R167H and GAPDH primers (Fischer-Scientific, Waltham, MA). CAG-F: 
5′-TCATATGCCAAGTACGCCCC-3′; CAG-R: 5′-CCCCATCGCTGCACAAAATA-3′; TP53-F: 5′-TGGCTC 
TCCTCAAGCGTATT-3′; TP53-R: 5′-ATTTTCATCCAGCCAGTTCG-3′. Bands displayed were run as shown 
and without modification.
Histology, immunohistochemistry, and immunofluorescence/immunocytochemistry. 
LSL-KRASG12D-TP53R167H pigs or were euthanized and subjected to pathological examination the pancreas, small 
intestine, liver, bile duct, lymph nodes, spleen, omenteum, colon, thyroid, lung, heart, kindeys, diaphragm, eso-
phagus, bladder, and stomach. Similarly, mice were sacrificed via cervical dislocation and xenograft tumors col-
lected. Tissues were fixed in 10% formalin, paraffin-embedded, and sections at 4 μm interval were cut from each 
tissue, and stained with H&E, trichrome (Sigma Aldrich, St. Louis, MO), or via immunohistochemistry (IHC)/
immunofluorescence (IF).
For IHC, slides were deparaffinized and heated in a pressure cooker using DAKO retrieval buffer (DAKO, 
Carpinteria, CA). Endogenous peroxidases were quenched in DAKO peroxidase block for 20 min. Tissues 
were blocked with 0.5% BSA in PBS for 30 min and exposed a primary antibodies against RASG12D (NewEast 
Biosciences, King of Prussia, PA), PCNA (Santa Cruz, Santa Cruz, CA), αSMA, Synaptophysin, Pancreatic 
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amylase (abcam, Cambridge, MA), Vimentin, E-Cadherin, mutant P53, and pERK (Cell Signaling, Danvers, MA) 
at 1:50-1:400 overnight at 4 °C. Slides were developed using an HRP-conjugated secondary antibody followed by 
DAB substrate/buffer (DAKO).
For IF, slides were deparaffinized and heated in a pressure cooker using DAKO retrieval buffer (DAKO, Carpinteria, 
CA). Endogenous peroxidases were quenched in DAKO peroxidase block for 20 min. Tissues were blocked with 0.5% 
BSA in PBS for 30 min and exposed a primary antibodies against CK19 (University of Iowa Hybridoma Bank, Iowa 
City, IA), pPancreatic amylase, αSMA, PCNA, (Santa Cruz), Vimentin, or pERK (Cell Signaling) at 1:100 overnight at 
4 °C. Slides were visualized using an Alexaflour-488 or 594 conjugated secondary (abcam).
For cultured cells, cells were grown on chamber slides and fixed with ice-cold methanol at −20 °C for 10 min-
utes. Cells were blocked for 1 hour at room temperature with 0.5% BSA in PBS, and incubated with primary anti-
bodies against CK19 (University of Iowa Hybridoma Bank), E-Cadherin, pERK, (Cell Signaling) or PCNA (Santa 
Cruz) at 1:50-100 overnight at 4 °C. Slides were visualized using an Alexaflour-488 or 594 conjugated secondary 
antibody (abcam).
Western blot and immunoprecipitation/RBD Assay. Cell or tissue lysates were lysed in 4% SDS buffer 
followed by needle homogenization. Equal amounts of protein (15–40 μg) were mixed with loading dye, boiled 
for 8 min, separated on a denaturing SDS–PAGE gel and transferred to a PVDF membrane. The membrane was 
blocked in 5% milk/TBS/0.1% Tween for 1 h and incubated with antibodies against pERK, ERK, Vimentin, (Cell 
Signaling, Danvers, MA, USA), αSMA (abcam), β-Actin (Santa Cruz Biotech, Santa Cruz, CA, USA). The mem-
brane was washed with TBS-0.1% Tween and then incubated with HRP conjugated secondary antibody (Santa 
Cruz Biotech) at room temperature for 1 h and rewashed. Protein bands were visualized by an enhanced chemi-
luminiscence method (Thermo, Waltham, MA, USA) and resolved digitally per the manufacturer’s specifications. 
For RAS activation assay, a standard kit was purchased and used per manufacturer specification (Thermo). All 
experiments were performed in triplicate unless otherwise specified.
Flow cytometry. Cultured pancreas cells were seeded into a round-bottom 96-well plate, washed in PBS, and 
stained with anti-RASG12D antibody (New East Biosciences) 1:100 in PBS with 1% BSA over ice for 20 minutes. 
Cells were analyzed with a BD Fortessa. All flow plots correspond to size appropriate single cells and are repre-
sentative of 100,000 events unless otherwise stated.
Study approval. All experiments involving the use of mice were performed following protocols approved by 
the Institutional Animal Care and Use Committee at the University of Illinois. Patient slides and information was 
obtained in a de-identified fashion from the Northwestern University Pathcore, following local IRB approval. All 
patients offered informed consent for study participation. All methods were performed in accordance with the 
relevant guidelines and regulations
Results
KRAS and TP53 mutations induce metastatic behavior in porcine pancreatic duct cells. To 
assess the viability of loxp-STOP-loxp (LSL)-KRASG12D-TP53R167H pigs as a potential model of PDAC, we first 
compared the microscopic anatomy of the human, murine, and porcine pancreas. Despite the described struc-
tural differences, we found that the gland histology was remarkably similar among the three species (Fig. S1). In 
light of these similarities, we next euthanized a 2-month-old female LSL-KRASG12D-TP53R167H pig and removed 
the pancreas gland. We then extracted and digested the main pancreatic duct to isolate duct cells, and infected 
them with 1 × 106 units of Adeno-Cre in vitro. Cells displayed normal ductal morphology and negligible prolifer-
ation 24 hours after transduction. However, 7 days following transduction, LSL-KRASG12D-TP53R167H expressing 
duct cells had self-immortalized, now displaying spindle shaped morphology consistent with malignant transfor-
mation (Fig. 1A). Additionally, transduced cells also demonstrated robust expression of the TP53R167H transcript/
protein (Figs 1B,C and S2A), as well as the mutant RASG12D protein as determined by immunocytochemistry and 
verified by both western blot and flow cytometry (Figs 1D,E and S2A). These transformed cells, named Porcine 
Carcinoma 1 (PORC1), strongly expressed E-cadherin and CK19, affirming their ductal lineage. Consistent with 
a tumorigenic phenotype, PORC1 cells also displayed increased RAS activation, as well as strong expression of the 
KRAS effector pERK1/2 and proliferation surrogate PCNA (Figs 1F and S2B).
We next injected 5–10 × 106 PORC1 cells either subcutaneously (SQ) or intraperitoneally (IP) into SCID mice 
(N = 7 per group). Mice with SQ injection developed large masses under the skin at each injection site (Fig. S3A), 
while mice with IP injection developed several large focal plaques on the abdominal viscera that were easily pal-
pable (Fig. 1G). SQ tumors were routinely measured and overall health was assessed by weight (Fig. S3B). Like 
human PDAC, these tumors had a dense, cellular stroma, with cancer cells staining for E-cadherin, indicating an 
epithelial origin. These epithelial cells were distinct from the fibrous component, which was evaluated by Masson’s 
Trichrome staining. Furthermore, like the PORC1 cells in vitro, xenograft tumors were highly positive for CK19, 
affirming a ductal lineage and expressed mutant RASG12D. Also consistent human PDAC tumors, the stroma had 
strong expression of αSMA, a marker of pancreatic stellate cells (Figs 1G and S3A).
Restriction of Adeno-Cre to the Main Pancreatic Duct Leads to a Predominantly Pancreatic Ductal 
Adenocarcinoma Histotype. Given the sufficiency of KRASG12D and TP53R167H mutations to transform 
pancreatic duct cells in vitro, we initiated autochthonous porcine pancreatic tumor formation in vivo. Our first 
attempts of intraparenchymal delivery of Adeno-Cre resulted in a mixed histotype of leiomyosarcoma and 
duct-derived neoplasms akin to those seen in human patients (N = 3, Figs S4 and S5, and Supplementary Results). 
Given the presence of clinically relevant pancreatic neoplasms, we next attempted to recreate the described 
duct-derived pancreas histotype pancreas histotype while avoiding the leiomyosarcoma phenotype observed 
in our initial experiments. Therefore, we repeated the above experiment focusing on transformation of ductal 
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Figure 1. Concomitant KRASG12D and TP53R167H Mutations Induce Metastatic behavior in Porcine Pancreatic 
Duct Cells ex vivo. (A) Primary pancreatic duct cells were isolated, placed into culture, and incubated with 
1 × 106 units of Adenoviral-Cre. After 7 days the cells, designated Porcine Carinoma 1 or PORC1, self-
immortalized and displayed more spindle shaped morphology (B,C) PORC1 cells were evaluated by RT-
PCR for the TP53R167H transcript. (D,E) Mutant RASG12D expression in PORC1 cells was confirmed using 
immunocytochemistry and flow cytometry. (F) PORC1 cells were validated using immunocytochemistry for 
the duct marker CK19, epithelial marker E-cadherin, as well as proliferation surrogate PCNA and the RAS 
effector pERK. (G) 5 × 106 PORC1 cells were injected intraperitoneally into severe combined immunodeficient 
(SCID) mice. After 16 days, the mice presented with gross tumors at the site of injection, which were sectioned 
and stained with H&E, Masson’s Trichrome, or via immunohistochemistry for E-cadherin, CK19/αSMA, and 
RASG12D (N = 7).
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epithelial cells rather than mesenchyme by surgically injecting 4 × 109 units of Adeno-Cre directly into the main 
pancreatic duct.
One year following injection, there were no overt signs of illness or pancreatic insufficiency as observed in 
the previous cohort. Similarly, contrast-enhanced computed tomography (CT) showed no evidence of gross 
tumor formation at the injection site or near the pancreas. Additionally, the hepatobilliary tract, spleen, liver, 
and regional lymph nodes appeared normal with no sign of lesions. The stomach was moderately filled with gas 
and fluid with a mild amount of hyper-attenuating material in the dependent region of the fundus, though there 
was no clear sign of overt abnormality (Fig. S6A). Furthermore, upon euthanasia, the pancreas displayed no 
overt signs of sarcoma and had three distinct lobes. However, on dissection, the main pancreatic duct was large 
and firm with several large, nodular tumors with a pronounced fibrous component at the site of cannulation 
(Fig. S6B).
Tumors were then fixed and sectioned, and compared directly to human PDAC samples. Upon histological 
evaluation of several geographically separate areas, porcine tumors consistently displayed morphological fea-
tures consistent with human PDAC (Fig. 2A,B). In addition to having no evidence of sarcoma or smooth muscle 
abnormality, there were several areas consisting of lumenal masses with considerable cellular atypia and invasion 
through the basement membrane (Fig. 2B). Like human PDAC, these lesions were accompanied by a dense and 
desmoplastic tumor stroma rich with leukocytes (Fig. 2A,B).
Consistent with a PDAC phenotype, porcine tumor sections were positive for both E-cadherin and CK19 
(Fig. 2C). Though the predominant histotype was derived from exocrine pancreas, there were distinct and geo-
graphically separate areas that appeared to have a phenotype more similar to pancreatic neuroendocrine tumors 
(PNET). We therefore compared these areas directly to human PNET sections, and found that they shared several 
histological features, including a less pronounced desmoplastic tumor stroma (Fig. S7A,B) and stained positive 
for the neuroendocrine marker Synaptophysin (Fig. S7C).
LSL-KRASG12D-TP53R167H-Induced PDAC Displays Excessive Proliferation. To assess changes in 
KRAS activity, we first performed a RAS activation assay using control and tumor tissues. As expected, in PDAC 
tissues, KRAS protein had increased GTP binding ratio compared to control tissues, and exhibited robust expres-
sion of KRASG12D and P53R172H proteins. These were accompanied by enhanced ERK activation as determined 
by western blotting (Fig. S8) and confirmed by immunohistochemistry, localizing pERK to areas suspect for 
PDAC (Figs 3A and S9A). These areas also stained strongly for PCNA, a surrogate marker of cell proliferation 
(Figs 3B and S9B), whereas adjacent normal tissue had little to no PCNA staining (data not shown). To affirm 
that these proliferating regions were indeed those previously identified as PDAC, we dual-stained tissues for both 
the ductal marker CK19 and PCNA. Regions proliferating most strongly were also CK19 positive, indicative of 
PDAC (Fig. 3C). Similarly, areas suspect for PNET also displayed robust ERK activation as well as PCNA staining, 
further suggesting the presence of endocrine-derived neoplasms (Fig. S7D).
Porcine PDAC Develops a Desmoplastic Stroma Analogous to Human Patients. As the pancre-
atic cancer stroma is not only a near uniform histological feature but also a key component of disease progres-
sion and chemo-resistance14,15, we analyzed the tumor microenvironment of both human and porcine PDAC 
sections. As expected, all human PDAC samples examined had a dense, desmoplastic tumor stroma that stained 
positive with Masson’s Trichrome (Fig. 4A). Porcine tumors were similarly desmoplastic with increased Collagen 
IA expression (Fig. S8) and also stained positive with Masson’s Trichrome (Fig. 4B). Similarly, expression of the 
mesenchymal marker Vimentin was increased (Fig. S8) and localized exclusively to the tumor stroma (Fig. 4C). 
As pancreatic stellate cells are considered the critical mediator of tumor-associated fibrosis16, we next assessed 
tumor sections for expression of αSMA, which was also localized to the stroma and was associated with areas of 
CK19-positive PDAC (Fig. 4D).
Discussion
The poor survival associated with pancreatic cancer stems largely from the fact that most patients initially present 
with highly advanced disease. As most of these patients are not candidates for surgical intervention and there 
is no effective pharmacological therapy, there is an urgent need to develop new therapeutic approaches. To do 
so, investigators have relied almost exclusively on genetically engineered mouse models. For example, the Pdx 
promoter has been used to drive Cre expression in the progenitor cells of the pancreas, which when crossed to 
a loxp-STOP-loxp (LSL) cassette resulted in a faithful recapitulation of the more common PanIN histotype17. 
Combining this model with an LSL-TP53R172H cassette resulted in a metastatic model of PDAC with histology 
closely resembling that observed in human patients10. These KPC mice have been favored by a number of inves-
tigators for this reason, and have provided a reliable and accurate model of human PDAC for over a decade. 
However, despite the success of the KPC mice, there are still the inherent limitations of the mouse anatomy and 
physiology that must be considered.
Importantly, the mouse pancreas has significant micro and macroscopic differences to that of humans. The 
human pancreas is a firm organ that is segmented into three borderless, yet distinct parts: the head, body, and 
tail18. In contrast, the mouse pancreas is soft and diffuse with three poorly defined lobes19. There are also pro-
nounced differences of the ductal tree between the two species. In humans, the pancreatic acini are the predomi-
nant exocrine cell type and are organized into lobules that secrete to a small, intercalated duct. These intercalated 
ducts drain to a larger, interlobular duct that join to form the large, main pancreatic duct which empties to 
the duodenum adjacent to the common bile duct18. In mice, however, a large interlobular duct drains the three 
respective lobes. Ducts from the splenic and gastric lobes then merge with the common bile duct far more prox-
imal to the duodenum than in humans18.
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In addition to these structural variances, there are several genetic factors that account for further differences 
in mouse and human carcinogenesis. Despite sharing a similar number of protein coding genes20, the mouse 
genome is substantially different from that of humans. Though much is shared, there is significant variance in 
transcriptional regulation and chromatin organization between the two species21. This is particularly true of genes 
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Figure 2. Restriction of Adeno-Cre to the Main Pancreatic Duct Leads to a Predominantly Pancreatic Ductal 
Adenocarcinoma Histoype. (A) Sections from human PDAC patients were stained with H&E demonstrating 
varied tissue architecture with common features including ductal lesions with cellular atypia and a dense 
tumor stroma. (B) Tumors from the LSL-KRASG12D-TP53R167H pig delivered an Adeno-Cre injection into the 
main pancreatic duct were sectioned and stained with H&E showing several histologic features consistent with 
PDAC. (C) Porcine tumors were next stained for the pan-epithelial marker E-cadherin or the duct marker 
CK19, affirming a PDAC histotype.
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involved in the inflammatory response22, indicating that mice may have limited utility in inflammation-associated 
diseases such as pancreatic cancer23. Another notable disparity between mouse and human genetics is the failure 
of mutations in Cystic Fibrosis Transmembrane Regulator (CFTR) gene to induce significant pancreatic disease 
as it does in humans24. These issues were resolved by modeling the disease in pigs, which lead to a more faithful 
recapitulation of the disease pathology and destruction of the exocrine pancreas25,26. We therefore attempted to 
recreate the success of the KPC model in the more genetically and anatomically similar sus scrofa domestic pig, in 
order to provide a more clinically relevant model of PDAC.
Initial attempts at intrapancreatic delivery of Adeno-Cre resulted in a mixed histotype. While the pigs devel-
oped PanIN lesions within 16 days, we also observed lethal smooth muscle derived leiomyosarcoma, likely due 
to the malignant transformation of vascular smooth muscle infected with Adeno-Cre. These two cancer types 
generally do not present simultaneously. Therefore, it was necessary to refine our approach in order to generate a 
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Figure 3. LSL-KRASG12D-TP53R167H-Induced PDAC Displays Excessive Proliferation. (A,B) To assess 
downstream RAS activity and cell proliferation, porcine tissues were stained via immunohistochemistry for 
pERK or PCNA, and compared to non-infected pancreas tissue of LSL-KRASG12D-TP53R167H pigs. Sections 
stained for pERK were scored based on intensity and scores averaged, showing increased ERK phosphorylation. 
Similarly, PCNA+ cells were quantified per 40X and compared to non-infected controls, indicating an increase 
in cell proliferation. (C) Sections were dual stained for CK19 and PCNA to localize cell proliferation to areas of 
PDAC. Dual positive cells per 40X field were then quantified and compared to non-infected pancreas tissue of 
LSL-KRASG12D-TP53R167H pigs.
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clinically relevant PDAC histotype. By restricting the delivery of our Cre using an intraductal injection, we were 
able to induce locally invasive PDAC without the presence of an underlying sarcoma. Interestingly, this approach 
also resulted in a somewhat mixed histotype, this time consisting of PDAC as well as rare and geographically 
isolated regions of PNET.
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Figure 4. Porcine PDAC Develops a Desmoplastic Stroma Analogous to Human Patients. (A,B) The tumor 
microenvironment from human PDAC patients and duct-injected LSL-KRASG12D-TP53R167H pigs were assessed 
via Masson’s Trichrome staining. (C) Pig tissue sections were stained for the mesenchymal marker Vimentin. 
(D) Sections were dual stained for CK19/αSMA to evaluate the presence of pancreatic stellate cells surrounding 
PDAC lesions.
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Mixed tumors and mixed adenoneuroendocine carcinomas (MANEC) of the gastrointestinal tract and pan-
creas have been well described by our group as well as many others27. They are commonly aggressive tumors 
most frequently occurring in the head of the gland and management is often a combination of surgery and 
platinum-based chemotherapy. At the present time, this may be the most appropriate category for tumors induced 
by LSL-KRASG12D-TP53R167H pigs, though PDAC appeared to predominate, particularly in sections closest to the 
main pancreatic duct. Therefore, future work will employ improved exocrine targeting to exclude the neuroen-
docrine compartment.
Based on the size and anatomy of the pig, this model may allow for insight into surgical and interventional 
radiology techniques never before possible in rodents. Pigs and humans also have largely analogous Cytochrome 
P450 enzymes, allowing for better pre-clinical evaluation of drug metabolism and therapy28. Additionally, given 
the profound similarity between human and pig immune systems, these LSL-KRASG12D-TP53R167H pigs may pro-
vide an improved platform for preclinical immunotherapy. Given these advantages, several porcine models of 
cancer are emerging. These include a mutant APC porcine model of familial adenomatous polyposis (FAP), a 
heterozygous TP53 knockout model of spontaneous osteosarcomas, and a chemically induced hepatocellular 
carcinoma (HCC) model29. Similarly, our inducible LSL-KRASG12D-TP53R167H model has successfully generated 
soft tissue sarcomas and HCC13,29,30.
By demonstrating sufficiency of the LSL-KRASG12D-TP53R167H pig to model a human-like pancreatic carci-
noma both in vitro and in vivo (Summarized in Fig. 5), we substantiate the pig as a more physiologically rele-
vant platform in which to model the two predominant pancreatic cancer histotypes, allowing for novel research 
approaches and bridging the gap from bench to bedside.
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